Evidence map›Paper›PMID 41531947›Full record

ArticleACS medicinal chemistry letters2026

Tambjamines as Promising Leads for the Development of Next-Generation Antifungals against

Amrendra Kumar, Ju-Hsin Chia, Kevin A Reynolds, Jane X Kelly, Papireddy Kancharla

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amrendra KumarDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.
Ju-Hsin ChiaPharmacology Discovery Services Taiwan, Ltd., New Taipei City 24891, Taiwan.
Kevin A ReynoldsDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID https://orcid.org/0000-0003-0270-9809
Jane X KellyDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID https://orcid.org/0000-0001-8871-0207
Papireddy KancharlaDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID https://orcid.org/0000-0002-6381-1236

Funding

Novel Multiple-Stage Active AntimalarialsR01AI141972 · NIAID · PORTLAND STATE UNIVERSITY · PI JANE X KELLY, Papireddy Kancharla · 2019 to 2026
$4.5M
Natural Product Inspired Novel Antimalarials with Radical Cure PotentialR01AI175444 · NIAID · PORTLAND STATE UNIVERSITY · PI JANE X KELLY, Papireddy Kancharla · 2023 to 2026
$2.5M
NIAID NIH HHS R01 AI141972NIAID NIH HHS R01 AI175444
6 · The paper itself

Abstract

Human fungal infections pose a major global health challenge, underscoring the urgent need for new chemotypes that are effective against multidrug-resistant (MDR) fungal pathogens such as

Indexed as

AntifungalsCandida albicansCandida aurisNatural productsTambjamines

Identifiers

PMID41531947
PMCPMC12794057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.